Efficacy comparison of rivaroxaban and low molecular weight heparin in the treatment of malignant tumors with venous thromboembolism
Objective To compare the efficacy of rivaroxaban and low molecular weight heparin in the treatment of malignant tumors with venous thromboembolism.Methods 68 patients with malignant tumors and venous thromboembolism were selected,and were divide into a control group and an observation group using a random number table,each with 34 cases.The control group was treated with low molecular weight heparin,while the observation group was treated with rivaroxaban.The coagulation function indicators,clinical efficacy,and follow-up related information were compared between the two groups.Results After treatment,the thrombin time(TT),prothrombin time(PT),activated partial thromboplastin time(APTT),D-dimer(D-D),fibrinogen(FIB)and international normalized ratio(INR)of the observation group were(16.90±1.29)s,(12.18±1.51)s,(27.77±4.54)s,(1.08±0.30)mg/L,(3.82±0.68)g/L,and(0.99±0.11),while those of the control group were(16.52±1.18)s,(12.13±1.45)s,(28.60±4.67)s,(1.12±0.33)mg/L,(3.90±0.79)g/L,and(0.97±0.08),and there was no significant difference between the two groups(P>0.05).The total effective rate of the observation group was 91.18%,the incidence of bleeding events was 8.82%,the recurrence rate was 11.76%,and the mortality rate was 2.94%,which had little difference compared with 88.24%,11.76%,14.71%,and 5.88%of the control group(P>0.05).Conclusion For the treatment of malignant tumors combined with venous thromboembolism,both rivaroxaban and low molecular weight heparin can achieve good results and are equally safe.Clinically,medication can be selected based on the specific situation of the patient.
万方数据
维普
